{
    "clinical_study": {
        "@rank": "26766", 
        "acronym": "FORTE", 
        "arm_group": {
            "arm_group_label": "Atorvastatin", 
            "arm_group_type": "Experimental", 
            "description": "Atorvastatin (Lipitor) will be prescribed with 20mg,40mg,or 80mg by the unit of 28 tablets upon the result of lipid profile. Besides Clinical and lab test, follow-up CAG, IVUS and FFR will be performed in 12 months."
        }, 
        "brief_summary": {
            "textblock": "Natural course of intermediate coronary artery disease (CAD) is very important to predict\n      the prognosis of the patient with such disease.\n\n      Several studies have well demonstrated the beneficial effect of lipid-lowering therapy on\n      the progression of CAD with the modification of lipid profiles.\n\n      This effect can be also explained by intravascular ultrasound (IVUS) or optical coherence\n      tomography. However, the effect of plaque modification on coronary physiology has been\n      rarely evaluated.\n\n      This research is to evaluate the change of intermediate or nonculprit coronary lesion on\n      lipid-lowering therapy via IVUS and FFR."
        }, 
        "brief_title": "Effect of Atorvastatin on Fractional Flow Reserve in Coronary Artery Disease", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "The patients who have intermediate CAD (30-80% diameter stenosis by visual estimation) with\n      FFR\u22650.80, or nonculprit coronary artery disease with FFR\u22650.8 after culprit coronary artery\n      disease intervention will be enrolled. FFR, IVUS and index of microcirculatory resistance\n      (IMR) should be performed simultaneously. Atorvastatin 20mg is a starting dose, then\n      up-titration will be done twice within each 4\u00b12weeks until LDL target goal (\u2460 LDL<70mg/dl,\n      or \u2461 statin naive: >50% reduction from baseline LDL, current statin user: >30% reduction\n      from baseline LDL). First titration will be atorvastatin 40mg, second will be atorvastatin\n      80mg. If patients have any adverse effect on atorvastatin, the dose of atorvastatin can be\n      adjusted by investigator's decision. Official clinical follow-up except visit for statin\n      dose titration will occur at 1, 12 months after index procedure. Follow-up coronary\n      angiography, FFR,IMR,and IVUS will be performed 12 months after index procedure."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patient > 18 years of age and willing to participate\n\n          -  patients who have stable intermediate CAD(30-80% diameter stenosis by   visual\n             estimation) on angiography with FFR\u22650.8,or who have nonculprit CAD which is not\n             planned revascularization\n\n          -  Signed written Informed Consent\n\n        Exclusion Criteria:\n\n          -  Patients who are in cardiogenic shock\n\n          -  Patients with LVEF<35%\n\n          -  Patients with left main disease, restenotic, bypass grafted lesions\n\n          -  Patients with platelet count < 100,000 cell/mm3\n\n          -  Patients who have co-morbidity which reduces life expectancy to one year\n\n          -  Patients who have a history of stroke or transient ischemic attack within 6 months\n\n          -  Patients who are planned discontinuation of medication due to surgery\n\n          -  Patients with known adverse reaction to HMG CO-A reductase therapy (statins)\n\n          -  Patients with liver disease (elevation of AST or ALT more than 2 times)\n\n          -  Patient with creatinine > 2.0 mg/dL\n\n          -  Pregnant women and women of childbearing potential who intend to have children during\n             the duration of the trial\n\n          -  Patients who consistently must take drugs affecting lipid levels in blood except the\n             investigational product"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "157", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01946815", 
            "org_study_id": "FORTE"
        }, 
        "intervention": {
            "arm_group_label": "Atorvastatin", 
            "description": "Lipitor dose titration will be followed by the result of LDL lab test until it meets the target level of LDL. IVUS and FFR during follow up CAG in 12 months will be measured to evaluate the effect of lipitor.", 
            "intervention_name": "Atorvastatin", 
            "intervention_type": "Drug", 
            "other_name": "lipitor"
        }, 
        "intervention_browse": {
            "mesh_term": "Atorvastatin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 17, 2013", 
        "location": {
            "contact": {
                "email": "namcwcv@gmail.com", 
                "last_name": "Chang-Wook Nam, Postdoctoral", 
                "phone": "82-53-250-8015"
            }, 
            "facility": {
                "address": {
                    "city": "Daegu", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Keimyung University Dongsan Medical center"
            }, 
            "investigator": {
                "last_name": "Chang-Wook Nam, Postdoctoral", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 3 Study of Effect of ATorvastatin on Fractional Flow Reserve in Coronary Artery Disease", 
        "overall_contact": {
            "email": "namcwcv@gmail.com", 
            "last_name": "Chang-Wook Nam, Postdoctoral", 
            "phone": "82-53-250-8015"
        }, 
        "overall_official": {
            "affiliation": "Keimyung University Dongsan Medical Center", 
            "last_name": "Chang-Wook Nam, Postdoctoral", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "changes of FFR between baseline and 12months follow-up", 
            "safety_issue": "No", 
            "time_frame": "up to 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01946815"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Keimyung University Dongsan Medical Center", 
            "investigator_full_name": "NAM, Chang-Wook", 
            "investigator_title": "Associate Professor of Internal Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change of FFR according to the degree of decreased LDL", 
                "safety_issue": "No", 
                "time_frame": "up to 1 year"
            }, 
            {
                "measure": "Change of % plaque volume, total atheroma volume & plaque compositions in lesion of interest", 
                "safety_issue": "No", 
                "time_frame": "up to 1 year"
            }, 
            {
                "measure": "Change of IMR", 
                "safety_issue": "No", 
                "time_frame": "up to 1 year"
            }, 
            {
                "measure": "Death including cardiac and noncardiac", 
                "safety_issue": "Yes", 
                "time_frame": "up to 1 year"
            }, 
            {
                "measure": "Myocardial infarction", 
                "safety_issue": "Yes", 
                "time_frame": "up to 1 year"
            }, 
            {
                "measure": "Target lesion and vessel revascularization rate", 
                "safety_issue": "Yes", 
                "time_frame": "up to 1 year"
            }, 
            {
                "measure": "CVA: hemorrhage and infarction", 
                "safety_issue": "Yes", 
                "time_frame": "up to 1 year"
            }, 
            {
                "measure": "side effect of statin : liver and muscle enzyme", 
                "safety_issue": "No", 
                "time_frame": "up to 1 year"
            }
        ], 
        "source": "Keimyung University Dongsan Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Keimyung University Dongsan Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}